

Investor Service Announcement no. 1/2007

Hørsholm, 19 February 2007

## **LifeCycle Pharma appoints Senior Vice President of Pharmaceutical Development**

*Summary: LifeCycle Pharma appoints key CMC specialist Peter G. Nielsen as Senior Vice President to further strengthen the company's Pharmaceutical Development*

LifeCycle Pharma A/S (OMX: LCP) today announced the appointment of Peter G. Nielsen as Senior Vice President of Pharmaceutical Development and CMC. Mr. Nielsen will join the company from 1 March 2007.

Mr. Nielsen will be responsible for building the CMC organization at LifeCycle Pharma, overseeing the areas of pharmaceutical, analytical and manufacturing development. Mr. Nielsen will play a pivotal role in aiding the rapid development of new product candidates in LifeCycle's expanding late stage product pipeline.

Peter G. Nielsen has spent most of his career at Novo Nordisk, most recently as Vice President for Formulation & Clinical Supplies in CMC Supply.

Peter has an extremely impressive track record in CMC development and he will be a huge asset to LifeCycle Pharma," said Dr. Flemming Ørnskov, President and CEO of LifeCycle Pharma. "We are in an exciting stage of development and we very much look forward to adding Peter's skills to those of other experienced team members in the company." added Dr. Ørnskov.

### **For further information please contact:**

#### **LifeCycle Pharma A/S**

Rachel Curtis Gravesen VP Investor & Public Relations

Tel. +45 36 13 29 17

LIFECYCLE PHARMA A/S  
KOGLE ALLÉ 4  
DK-2970 HØRSHOLM  
WWW.LIFECYCLEPHARMA.COM  
TEL. +45 7033 3300  
FAX +45 3613 0319  
CVR. 26 52 77 67  
INFO@LCPHARMA.COM

Page 1 of 2

Mob: +45 25 12 62 63

Email: [rcg@lcpharma.com](mailto:rcg@lcpharma.com)

--oo0oo--

**About LifeCycle Pharma:**

LifeCycle Pharma is an emerging speciality pharmaceutical company with a broad and late stage product pipeline in therapeutic areas of cholesterol management, hypertension and organ transplant. LifeCycle Pharma's most advanced product has been filed with the US FDA and is expected to enter the US market in the first quarter of 2008. LifeCycle Pharma's product candidates are proprietary and designed to improve the quality of existing drugs by enhancing the release and absorption of drugs in the human body. LifeCycle Pharma's proprietary technology platform, MeltDose® technology, offers lower dosing, reduced side effects and improved safety and patient compliance as well as reduced product development time and production costs. LifeCycle Pharma has formed several partnerships with major pharmaceutical companies and is clinically developing product candidates within a number of areas, including cholesterol management, hypertension and organ transplant. LifeCycle Pharma is listed on the OMX Nordic Exchange under the trading symbol (LCP). Please visit [www.lcpharma.com](http://www.lcpharma.com) for further information about LifeCycle Pharma A/S.